Pay after cure
THE French- controlled us drug company, Rhone-Poulenc Rorer (RPR) has initiated a novel concept in selling its cancer drugs in the UK. Their sales representatives have an interesting message to convey: if the drug does not cure, payment need not be made. RPR is willing to bear the financial expenses if its drug does not live upto its promise of curing the patient.
It has recently won approval from all the 15 European Union states for its new cancer drug, Taxotere, and has begun the innovative sales pitch to promote it. Says Tom Foy, RPR'S oncology business unit director, "In other industries, if a product does not do what the maker says it does, you get taken to court. That doesn't happen in healthcare, so we are prepared to carry the financial burden of the drug in patients on whom the drug doesn't work."
Its nearest competitor in the breast cancer market is the Taxol drug made by Bristol-Myers Squibb, a US company. Both these drugs are made from derivatives of the Pacific yew tree and are powerful cancer-cell killers. However, they could cause damage to the nerves in certain patients.
Related Content
- Order of the Supreme Court of India regarding the need for setting up rehabilitation homes, 25/02/2019
- Ebola fight has new science but faces old hurdles in restive Congo
- Ghana records 80% increase in new cases of HIV/AIDS in 2017
- Ray of hope as new vaccine 'cures' five Aids patients in seven months
- Guidelines for Disposal of Thermoset Plastic Waste including Sheet moulding compound (SMC)/Fiber Reinforced Plastic (FRP)
- A profile of heavy metals in rice (Oryza sativa ssp. indica) landraces